Document Detail


Identification of a nicotinic acid receptor: is this the molecular target for the oldest lipid-lowering drug?
MedLine Citation:
PMID:  15083592     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nicotinic acid has been used clinically for over 40 years in the treatment of dyslipidemia, producing a desirable normalization of a range of cardiovascular risk factors. The precise mechanism of action of nicotinic acid is unknown, although it is believed that activation of a Gi-type G protein-coupled receptor, resulting in the inhibition of adipocyte lipolysis, may contribute. This review describes the identification of this elusive receptor, and outlines the evidence suggesting that this may be the molecular target for the clinical effects of nicotinic acid.
Authors:
Nicholas B Pike; Alan Wise
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in investigational drugs (London, England : 2000)     Volume:  5     ISSN:  1472-4472     ISO Abbreviation:  Curr Opin Investig Drugs     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-04-15     Completed Date:  2004-07-06     Revised Date:  2011-10-13    
Medline Journal Info:
Nlm Unique ID:  100965718     Medline TA:  Curr Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  271-5     Citation Subset:  IM    
Affiliation:
Cardiovascular and Urogenital Centre of Excellence for Drug Discovery, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK. nick.b.pike@gsk.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Drug Delivery Systems
Furans / chemistry,  pharmacology
Humans
Hypolipidemic Agents / chemistry,  pharmacology*
Ligands
Niacin / chemistry,  pharmacology*
Receptors, G-Protein-Coupled
Receptors, Nicotinic / drug effects*,  metabolism
Chemical
Reg. No./Substance:
0/Furans; 0/HCAR3 protein, human; 0/Hypolipidemic Agents; 0/Ligands; 0/Receptors, G-Protein-Coupled; 0/Receptors, Nicotinic; 59-67-6/Niacin; 72420-38-3/acifran

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  [Characteristics of body constitution and their relations to success in learning].
Next Document:  Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.